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Abstract
Splice products of the Kiss1 protein (kisspeptins) have been shown to be involved in a diverse range of functions, including
puberty, metastasis and vasoconstriction in large human arteries. Circulating Kisspeptin-10 (Kp-10) plasma levels are low in
normal individuals but are elevated during various disease states as well as pregnancy. Here, we investigated the potential
of Kp-10, the shortest biologically active kisspeptin, to influence microvascular effects, concentrating on the cutaneous
vasculature. Kp-10 caused a dose-dependent increase in oedema formation (0.3–10nmol/injection site), assessed by Evans
Blue albumin dye extravasation, in the dorsal skin of CD1 mice. Oedema formation was shown to be inhibited by the
histamine H1 receptor antagonist mepyramine. The response was characterised by a ring of pallor at the injection site in
keeping with vasoconstrictor activity. Therefore, changes in dorsal skin blood flow were assessed by clearance of
intradermally injected
99mtechnetium. Kp-10 was found to significantly reduce clearance, in keeping with decreased blood
flow and providing further evidence for vasoconstrictor activity. The decreased clearance was partially inhibited by co-
treatment with the cyclo-oxygenase inhibitor indomethacin. Finally evidence for the kisspeptin receptor gene (Kiss1R), but
not the kisspeptin peptide gene (Kiss1), mRNA expression was observed in heart, aorta and kidney samples from normal and
angiotensin II induced hypertensive mice, with similar mRNA levels observed in each. We have evidence for two peripheral
vasoactive roles for kisspeptin-10. Firstly, plasma extravasation indicative of ability to induce oedema formation and
secondly decreased peripheral blood flow, indicating microvascular constriction. Thus Kp-10 has vasoactive properties in the
peripheral microvasculature.
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Introduction
The Kiss1 gene encodes a 145-amino acid protein that is cleaved
into a 54-amino acid peptide known as kisspeptin-54 (Kp-54) as
well as shorted peptides of 14, 13 or 10 amino acids [1]. These
peptides, collectively referred to as kisspeptin, have a wide range of
functions in different tissues and physiological processes. Upon its
discovery in 1996, Kp-54, also known as metastin, was found to
inhibit metastasis of malignant melanoma cells [2] which has since
been replicated in breast cancer cells treated with Kp-10(Kp-10)
[3]. This ability to inhibit the migration of cells was further
confirmed when the movement of primary trophoblasts, crucial for
placental development during pregnancy, was halted by Kp-10
treatment [4]. However, the most important role of kisspeptin is
currently considered to be its control of reproductive function.
Inactivating mutations of the Kp-10 receptor (Kiss1R, also known
as GPR54) in humans are associated with failure to progress
through puberty and adult infertility (hypogonadotropic hypogo-
nadism) [5,6]. Similar defects were found in GPR54 knockout
mice [5]. Kp-10 stimulates secretion of the gonadotropic
hormones luteinising hormone (LH) and follicle-stimulating
hormone (FSH) [7] via a direct action on the hypothalamic
gonadotropin releasing hormone (GnRH) neurones which contain
Kiss1R [8]. Not only is Kp-10 the most potent activator of
gonadotropic hormone secretion, but it plays a key role in
regulating GnRH pulse generator frequency a critical component
controlling the hypothalamo-pituitary-gonadal axis [9].
Recently it has been suggested that members of the kisspeptin
family may also possess vasoactive activity. Kp-10 has been shown to
inhibit the migration of human umbilical vein endothelial cells and
subsequent angiogenesis through inhibition of vascular endothelial
growth factor (VEGF) signalling [10]. Additionally, Mead et al (2007)
identified transcription of both Kiss1 and Kiss1R mRNA in human
aorta, umbilical vein and coronary artery but not other vessels [11]. It
was further suggested that Kp-10, -13 and -54 may be novel
vasoconstrictors in vivo as all three peptides resulted in contraction of
human vessels in myograph studies with comparable potency to
angiotensin II (Ang II), a potent vasoactive peptide [11]. Also,
endothelial cells were postulated to be an alternative source of
kisspeptin, possibly contributing to circulating plasma levels or acting
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large conductance vessels. By comparison, the smaller vessels of the
microvasculature are important for controlling tone and other
vasoactive effects, where increases in permeability to plasma proteins
lead to plasma extravasation and oedema formation.
Circulating plasma Kp-10 levels in normal individuals are believed
to be low. However, the concentration of Kp-10 increases from
1.3fmol/ml pre-pregnancy to 9.6pmol/ml in the third trimester [12].
T h es o u r c eo ft h i si n c r e a s ei sb e l i e v e dt ob et h ep l a c e n t a ,a sK p - 1 0
levels drop almost immediatelyafter birth [12]. The vascular effects of
Kp-10 may be important as hypertension and oedema are symptoms
ofpre-eclampsiaprevalentinlate-termpregnanciesbutnotafterbirth
[13]. It has been shown that trophoblasts from women with pre-
eclampsia have significantly higher kiss1 mRNA and Kp-54 peptide
levels than trophoblasts during normal pregnancies [14]. By
comparison, contrasting data has also been published suggesting that
serum from women with pre-eclampsia contain less Kp-10 than
control individuals [15]. At present it is known that circulating levels
are sufficient to influence vascular function in physiological situations.
However,kisspeptin’seffectineithersituationwhere circulatinglevels
are high or where there are high local levels, as observed within the
placenta during late pregnancy, may well influence local vasoactive
events. With this concept in mind we have utilised established
procedures for assessing microvascular blood flow and plasma
extravasation in the cutaneous microvasculature of laboratory mice
to investigate the ability of Kp-10 to influence vasoactive effects at the
microvascular level. We have previously shown in studies of the
cutaneous microvasculature and in similar in vivo assays that i)
calcitonin gene-related peptide (CGRP) is one of the most potent
vasodilators known [16] ii) endothelin-1 (ET-1) has the ability to
mediate microvascular vasoconstriction [17] and iii) alarin (a novel
member of the galanin family of peptides) mediates vasoconstrictor
activity [18].
Here, we investigated the microvascular effects of Kp-10, the
shortest biologically active proteolysis product of the Kiss1 gene, in
the peripheral microvasculature of mice. The study was controlled
through comparison with the known microvascular activities of the
neuropeptides substance P, CGRP and endothelin-1.
Materials and Methods
Ethics
Experiments were carried out under the U.K. Animals
(Scientific Procedures) Act, 1986 under licence # PPL 70/6899.
Procedures were also approved by the Kings College London local
ethical review committee. All animals were maintained on a
normal diet, with free access to food and water, in a climatically
controlled environment.
Animals
Female and male CD1 and C57BL/6 mice (approximately 25g,
8–12 weeks old) were obtained from Charles River (Kent, U.K.).
Reagents
All reagents were purchased from Sigma-Aldrich (U.K.) unless
specified. Human Kp-10 was purchased from Alta Bioscience
(Birmingham, U.K.). CGRP was purchased from Cambridge
Bioscience (Cambridge, U.K.). All peptides were dissolved in
distilled water and stored at 220uCo r280uC until further
dilution in saline immediately prior to use.
Measurement of Plasma Extravasation
Mice were anaesthetised with urethane (25% w/vol; 2.5 g/kg
i.p.), and the dorsal skin was shaved. Plasma extravasation was used
as an indication of oedema formation and assessed using an Evans
Blue accumulation assay in skin, as described by Cao et al (1999)
[19]. Mice received Evans Blue (25% w/vol; 2.5mg/g i.v.) and after
3 minutes plasma extravasation was induced by an intradermal
injection (50mL per site) containing saline, Kp-10 (0.3–10nmol)
substance P (300pmol), CGRP (10pmol), histamine (20nmol), p234
(1nmol) or mepyramine (5nmol). In order to prevent site-related
effects, injection sites were randomised on the dorsal skin. Plasma
extravasation was quantified at different time points (7.5, 15 or
30 minutes) through pre-injecting at these time points prior to
cervical dislocation. The diameter of the blue lesion was measured
twice, at 90uC angles in order to provide an approximate area as
previously described [20]. Each site was also assessed for intensity of
blueness using a qualitative score of 0 (no blue, thus no evidence of
plasma extravasation) to 5 (darkest blue indicative of highest plasma
extravasation). The mean of the results for each site was determined
and results for the quantitative diameter assay to show spread of
plasma extravasation and the qualitative assay to show the intensity
of the plasma extravasation are shown.
Assessment of Changes in Blood Flow
Blood flow was assessed using a clearance technique in skin, as




immediately prior to use. Saline, Kp-10 (3–10nmol), endothelin-1




i.d.; Nuclear Medicine , Guy’s Hospital, London) in the dorsal skin
of male and female CD1 mice (50mL per site). An equal volume of
agent(s) under test +
99mTc was used for measurement of total
radioactivity. A 10 min clearance period was used, where
radioactivity cleared from the skin in proportion to blood flow
through the skin [21]. The clearance period was instantly
terminated by cervical dislocation and death, which reduced
blood flow to zero. The injected sites were then rapidly punched
out (11mm diameter) and the remaining radioactivity immediately
counted in an adjacent radioactive gamma counter. Clearance was
calculated by comparison of paired skin punch and total
radioactivity readings. Test agent specific clearance was then
calculated by comparison to saline controls, normalised to 100%,
and expressed as % change in clearance compared to control.
Positive values are due to decreased clearance that is directly
related to decreased blood flow and vasoconstrictor activity.
Mouse Model of Angiotensin II Induced Hypertension
In order to possibly learn more of the potential of Kp-10 to
influence cardiovascular dysfunction, gene expression was evalu-
ated in different tissues collected from hypertensive animals.
Hypertension was induced as described by Liang et al (2009) [22].
Briefly, Alzet osmotic minipumps (Charles River, U.K.) with a 14
day capacity, average volume of 100mL and an infusion rate of
0.25ml/hour were filled with saline or angiotensin II (adjusted to
mouse weight to deliver 1.1mg/kg/day, a dose previously shown
to induce hypertension [23] were implanted subcutaneously in
wild type (WT) female C57BL/6 mice in the mid-scapular region
under isoflurane anaesthesia. Mice were terminated after 14 days
by cervical dislocation and heart, aorta and kidneys collected.
Vehicle treated animals were used as controls. Tissues were
immediately immersed in RNAlater (Ambion) for 24 hours, snap-
frozen and stored at 280uC until analysis.
Quantitative mRNA Expression Analysis
Expression of Kiss1 and Kiss1R mRNA in homogenised tissues
was determined by real-time quantitative PCR using the Syber
Vasoactive Potential of Kp-10
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using the RNeasy Fibrous Tissue kit and (Qiagen, U.K.) and
reverse transcribed to cDNA using the High Capacity RNA-to-
cDNA kit (Applied Biosystems) according to the manufacturer’s
instructions. Real-time PCR was performed using the Sensimix
SYBER One Step Kit (Bioline). The following primers were
chosen and designed previously (Sigma) [24]: mouse Kiss1 sense:
ttcttggcagctgctgctt, antisense: cgaaggagttccagttgtag (product:
319 bp, Tann 55uC); mouse Kiss1R: sense: ggctccgtccaacgcttcag,
antisense: tgtgcttgtggcggcagata (product 175 bp, Tann 58uC).
Results are expressed as copy number and normalised by
comparison to reference genes HPRT-1, SDHA and PLA2 using
GeNorm version 3.4. All experiments were performed in
accordance with the MIQE guidelines [25].
Statistical Analysis
Results are displayed as mean 6 SEM. Statistical analysis was
performed using one way ANOVA followed by a Dunnet’s or
Bonferroni’s multiple comparison test or a paired two-tailed
Student’s t-test as indicated. Significance was accepted when
p#0.05. N represents the number of animals used in each
experiment.
Results
Kp-10 Caused a Dose-Dependent Increase in Plasma
Extravasation
Increases in plasma extravasation and subsequent oedema were
assessed by an Evan’s Blue dye technique. This dye binds to
albumin present in plasma following i.v. injection and exudation
after intradermal injection of vascular permeability increasing
agents is observed as a blue ring in the skin. The measurement of
this can be either as diameter of blueing, to show the spread of
plasma extravasation, or as intensity to give an estimation of the
amount of leakage. As expected, substance P (300pmol/site) but
not CGRP (10pmol/site) caused significant plasma extravasation
in the dorsal skin (Figures 1 & 2) [19]. Substance P-induced plasma
extravasation was potentiated by co-treatment with the vasodilator
CGRP (Figure 2). A dose-dependent increase in plasma leakage
was observed in Kp-10 treated animals (0.3–10nmol/site) as
assessed by area after 30 minutes (Figure 1). Plasma extravasation
was observed at 1–3nmol/site Kp-10 but was not significant.
However, treatment with 10nmol/site Kp-10 produced significant
plasma extravasation similar to that of the well characterised
permeability agent substance P. Additionally, the plasma extrav-
asation caused by Kp-10 (3nmol/site; 30 min) was potentiated by
the co-injection with CGRP (10 pmol/site) (Figure 2). The
similarity between the two different types of measurements is
noted.
Kisspeptin-Mediated Plasma Extravasation is an Acute
Response
To assess the duration of action of kisspeptin-mediated plasma
extravasation formation, mice were treated i.d. with test agents
and the experiment terminated after 7.5, 15 or 30 minutes. Plasma
extravasation was then assessed as previously described (Table 1).
As expected, Kp-10 (0.3–10nmol/site) induced a dose-dependent
plasma extravasation at all evaluated time points. The onset of
plasma extravasation was visible in less than 7.5 minutes. Minor
increases in permeability were observed after 15 minutes but
clearance of 1 and 3 nmol/site Kp-10 mediated plasma
extravasation may have occurred between 15 and 30 minutes
post-treatment leading to decreases in plasma extravasation area.
No difference in plasma extravasation was observed between time
points when Kp-10 was injected at 10 nmol/site, which produced
the highest observed levels of plasma extravasation.
Inhibitor Effect of a Histamine Antagonist on Kp-10
Induced Plasma Extravasation
In order to investigate the role of mast cell released histamine in
Kp-10 mediated plasma extravasation formation, female CD1
mice were co-treated intradermally with Kp-10 (10nmol/site),
histamine (20nmol/site) or substance P (300pmol/site) and
mepyramine (5nmol/site), a histamine H1 receptor antagonist
[26]. Histamine, substance P and Kp-10 injection caused
significant plasma extravasation formation in the dorsal skin
15 minutes post-injection when compared to control (saline)
(Figure 3). Substance P-treated sites were unaffected by co-
treatment with mepyramine. However, in the presence of
mepyramine both histamine- and Kp-10- mediated plasma
extravasation was abolished.
Figure 1. Kisspeptin-10 causes a dose-dependent increase in oedema formation in the cutaneous vasculature. Female CD1 mice were
anaesthetised, injected with Evans Blue dye i.v. and treated intradermally in the dorsal skin with 0.3–10nmol kisspeptin-10 (KP), 300pmol substanceP
(SP) or saline control (Veh) for 30 minutes. An uninjected site was also included (Un). Plasma exudation was allowed to continue for 30 minutes post-
injection at which point mice were killed, dorsal skin removed and the area of oedema measured (A). The lesion was also scored for colour intensity
(B). Results are shown as mean area (mm
2) 6 SEM, N=4.*=p#0.05, **=P#0.01, ***=p#0.001 assessed by one-way ANOVA compared to vehicle
control.
doi:10.1371/journal.pone.0014671.g001
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extravasation using p234, a Kp-10 derived antagonist of Kiss1R
[27]. However, when injected at 1 nmol/site, p234 caused a
marked plasma extravasation with an area of 60.765.3mm
2
(N=3). This plasma extravasation was also abolished by co-
treatment with 5nmol/site mepyramine.
Kp-10 Induced Plasma Extravasation Presents with a
Pallor Ring at the Injection Site
Upon observation of the oedema mediated by Kp-10 treatment
it was clear that, unlike substance P induced plasma extravasation,
a pallor ring was present at the injection site (Figure 4). This region
of plasma extravasation inhibition was measured 7.5 and
15 minutes post-treatment (Figure 5). After 7.5 minutes this area
of plasma extravasation inhibition was visible in both 3 and
10nmol Kp-10 treated injection sites, where they were of equal
magnitude. However, after 15 minutes of plasma leakage the
pallor size of the 10nmol Kp-10 treatment had increased, whereas
the inhibition observed at 3nmol had not. A small area of
inhibition was present in 1nmol Kp-10 injection sites after
15 minutes but this was not significant.
Kp-10 Decreased Blood Flow in the Peripheral
Vasculature
Mice were injected intradermally with Kp-10 (3–10 nmol/site),
endothelin-1 (30 pmol/site) or vehicle containing equal amounts
of
99mTc. After ten minutes, animals were culled and the skin
samples were obtained. The remaining radioactivity in each
injection site was compared to a control sample of total
radioactivity injected into a tube (Figure 6). Endothelin , an
established vasoconstrictor agent [28], endothelin-1 caused a
significant decrease in clearance from the injection site (60%
decrease from vehicle at a dose of 30pmol, p#0.01. At 3 nmol/
site, Kp-10 treatment resulted in a negligible decrease in clearance
compared to vehicle control. However, at 10 nmol/site Kp-10
caused a significant decrease in blood flow from 3 nmol/site
suggesting vasoconstrictor activity in the peripheral vasculature
(p#0.05).
3.6. Indomethacin Reduced Kp-10 Induced Decreased
Blood Flow
To investigate the mechanisms underlying Kp-10induced
decreases in peripheral blood flow, female CD1 mice were co-
treated intradermally with vehicle (5% NaHCO3/saline), 30pmol/
site endothelin-1 or 10nmol/site Kp-10 in the presence or absence
of 3nmol/site indomethacin, an inhibitor of cyclooxygenase,
containing equal amounts of
99mTc (Figure 7). After ten minutes,
indomethacin alone caused no change in blood flow compared to
vehicle. As previously demonstrated, 30pmol/site endothelin-1
caused a significant decrease in blood flow which was not shown to
be altered by co-treatment with indomethacin. However, 10nmol/
site Kp-10 induced vasoconstriction was significantly reduced
(p#0.05), but not totally inhibited, by co-treatment with
indomethacin.
Kiss1R mRNA, but not Kisspeptin, is Expressed in the
Kidney, Heart and Aorta
C57BL/6 mice were infused with 1.1mg/kg/day angiotensin II,
a dose previously shown to significantly increase systolic blood
Figure 2. Kp-10 induced oedema is potentiated by CGRP. Female CD1 mice were anaesthetised, injected with Evans Blue dye i.v. and treated
intradermally in the dorsal skin with 10pmol CGRP, 300pmol substance P (SP), 3nmol Kp-10 (KP), 10pmol CGRP +3pmol SP (S + C), 3nmol Kp-10 +
10pmol CGRP (K + C) or saline control (Veh) for 30 minutes. An uninjected site was also included (Un). Plasma exudation was allowed to continue for
30 minutes post-injection, mice were killed, dorsal skin removed and the area of oedema measured (A). Lesion colour intensity was also assessed (B).
Results are shown as mean area (mm
2) 6 SEM. N=8. *=p#0.05, **=p#0.01, ***=p#0.001 assessed by one-way ANOVA compared to vehicle
control.
doi:10.1371/journal.pone.0014671.g002
Table 1. Kisspeptin-10 mediated oedema formation is visible
7.5 minutes post-injection.
Time (Minutes)
KP (nmol/site) 7.5 15 30
0.3 5.2061.74 23.568.84 060
1 20.864.75** 21.765.30 7.7563.50
3 39.264.26*** 43.7610.7*** 20.568.13
10 38.4610.5*** 47.866.41*** 45.5611.7*
Female CD1 mice were anaesthetised, injected with Evans Blue i.v. and treated
intradermally with 0.3–10nmol Kp-10 (KP) in the dorsal skin for 7.5, 15 or
30 minutes. Mice were killed, the dorsal skin removed and the area of oedema
measured. Results are shown as mean area (mm
2) 6 SEM (3 s.f.). 7.5, 15 and
30 minute treatment groups consisted of N=5,N=6 and N=4 respectively.
*=p#0.05,
**=p#0.01,
***=p#0.001 compared to vehicle controls as assessed by one way ANOVA
followed by a Dunnet’s post test.
doi:10.1371/journal.pone.0014671.t001
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hypertensive animals exhibited systolic pressure readings of
12963.8mmHg compared to controls (11860.99mmHg). Hearts,
aortas and kidneys were removed and analysed for Kiss1 and
Kiss1R mRNA expression (Figure 8). Kp-10 mRNA was expressed
at low copy numbers under both conditions, unlike Kiss1R which
was expressed at higher levels in all three tissues but did not
increase after exposure to angiotensin II.
Discussion
Kisspeptins have been shown to possess well characterised
responses in puberty and reproduction [29], but little is known
about their cardiovascular effects. It has been suggested that
kisspeptins may be potent vasoconstrictor compounds [11]. This
study presents evidence that kisspeptins have the potential to
mediate effects in the peripheral microvasculature.
A novel insight into Kp-10 biology gained during this study was
the ability of Kp-10 to increase plasma extravasation, measured by
both the spread of the plasma extravasation, and through an
indication of intensity of staining, determined following Evans Blue
accumulation. This was an acute response, visible at 7.5 minutes
post-treatment, increasing in a dose-dependent manner, but
requiring approximately a 30 times greater dose than that for
substancePtoelicitasimilarplasmaextravasationarea.Theplasma
extravasation induced by Kp-10 was found to be histamine
mediated, as co-administration of mepyramine, a histamine H1
receptor antagonist [26] , abolished plasma extravasation. An
obvious explanation for this phenomenon is Kp-10 induced mast
cell degranulation. This is a characteristic shared by substance P in
some tissues, whereby a hydrophobic amino acid sequence and
terminal basicresidue arerequired tostimulate mast cells,leadingto
release of histamine and other inflammatory mediators [30].
Accordingly, Kp-10 possesses characteristics similar to these
structural elements. Substance P can also cause plasma extravasa-
tion via a histamine-independent mechanism, as observed here,
providing a positive control in this study [31]. The use of a Kiss1R
peptide antagonist p234, was attempted. However this possessed an
increased hydrophobocity due to the addition of an N-terminal
acetyl group [27], and was also shown to cause plasma
extravasation. The lack of pallor ring at the injection site suggests
that p234 is unable to stimulate vasoconstriction, most likely due to
Kiss1R antagonism. This potentially identifies it as a functioning
antagonist, but was not suitable for use locally in skin. Non peptide-
based Kiss1R antagonists have been developed which may be more
beneficial for future studies [32].
Kp-10 was shown to decrease peripheral blood flow as assessed
by
99mTc clearance from injection sites. However, it is noted that
in the murine cutaneous microvasculature endothelin-1 is at least
Figure 3. Mepyramine inhibits Kp-10 induced oedema formation. Female CD1 mice were anaesthetised, injected with Evans Blue i.v., and
then exposed intradermally to saline (Veh), 20nmol Histamine (His), 300pmol substance P (SP) and 10nmol Kp-10 (KP) +/25nmol Mepyramine (Mepy)
for 15 minutes. Mice were then killed, dorsal skin removed and the oedema area measured (A). Lesion colour intensity was also assessed (B). Co-
treatment with saline is indicated by white bars and co-treatment with mepyramine is indicated by black bars. Results shown as mean area (mm
2) 6
SEM, N=4. n.s.=no significant difference between treatments, ***=p#0.001 between mepyramine untreated and treated groups as assessed by two
way ANOVA.
doi:10.1371/journal.pone.0014671.g003
Figure 4. Kisspeptin induced oedema presents with a pallor
ring at injection site in the dorsal skin. Female CD1 mice were
anaesthetised, injected with Evans Blue i.v. and treated intradermally in
the dorsal skin with 10pmol CGRP, 300pmol substance P (SP), 10nmol
Kp-10 (K10), 10nmol Kp-10 +300pmol substance P (K + SP), 300pmol
substance P +10pmol CGRP (SP + CGRP) or 10nmol Kp-10 +10pmol
CGRP (K + CGRP). Plasma extravasation was allowed to continue for
30 minutes. Mice were killed, the dorsal skin removed and photo-
graphed. Pallor ring present in Kp-10 mediated oedema, but not under
other conditions, is indicated.
doi:10.1371/journal.pone.0014671.g004
Vasoactive Potential of Kp-10
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extravasation presented with a pallor ring of inhibition at its
centre. This is consistent with previous findings whereby Kiss1R
activation leads to increases in intracellular Ca
2+ concentration
[33] necessary for contraction of vascular smooth muscle cells
[34]. However, inhibition of prostaglandin and thromboxane
production by treatment with the cyclooxygenase antagonist
indomethacin partially reduced Kp-10 mediated vasoconstriction.
Kisspeptins have previously been shown to cause arachidonic acid
liberation, the substrate for cyclooxygenases, in CHO cells [33].
The most likely cyclooxygenase-derived mediator of Kp-10-
induced decreases in peripheral blood flow is the potent
vasoconstrictor thromboxane A2 [35]. The vasoconstriction
reported in this study supports previous work suggesting
kisspeptins cause constriction of several, but not all, human blood
vessels [11], but we were unable to assess the contribution of
Kiss1R activation to vasoconstriction due to the unsuitability of
p234 as an antagonist.
An assessment of Kiss1 and Kiss1R mRNA expression levels in
the heart, aorta and kidney was also performed. In agreement with
previous studies in humans tissues Kp-10 expression levels were
negligible [12,36], even after treatment with a well known
hypertensive agent (angiotensin II) [37]. In contrast, Kiss1R
expression was present in all three tissues, but did not increase
during hypertension either. This provides evidence that up-
regulation of vascular-derived Kp-10 does not play a primary role
in the onset of hypertension, although receptors are present in
vascular tissues to respond to circulating or locally produced
kisspeptin. In support of this concept, a recent publication was not
able to provide a positive link between circulating Kp-10 levels
and blood pressure changes [38].
Kiss1R has previously been shown to be expressed in the
developing embryonic kidney and at birth in mice [39]. However,
studies in human tissues have suggested that expression of both
Kiss1 and Kiss1R mRNA is high in the brain and placenta, but low
in both heart and kidney tissue [33,36]. Pre-eclampsia, of which
Figure 5. Pallor inhibition ring at centre of kisspeptin mediated
oedema increases in a dose dependent manner. Female CD1
mice were anaesthetised, injected with Evans Blue i.v. and treated
intradermally in the dorsal skin with 0.3–10nmol Kp-10 (KP), 300pmol
substance P (SP) or saline control (vehicle) in the dorsal skin. An
uninjected site was also included (Un). Plasma extravasation was
allowed to continue for 15 minutes. The skin was removed and the
region in which oedema was inhibited (pallor area) measured. N=6.
Results are shown as mean area (mm
2) 6 SEM. *=p#0.05, as assessed
by one-way ANOVA compared to vehicle control.
doi:10.1371/journal.pone.0014671.g005
Figure 6. Kisspeptin-10 decreases blood flow in the peripheral
vasculature. Male and female CD1 mice were anaesthetised, injected
intradermally via the dorsal skin with 3 or 10nmol KP-10 (KP) or 30pmol
Endothelin-1 (ET-1), each containing an equal amount of
99mTc.
Clearance after ten minutes was assessed and compared to total
radioactivity in an uninjected sample. Saline vehicle was adjusted to
100% and results displayed as a % change to controls. Results are
shown as mean 6 SEM, N=5. *=p#0.05, **=p#0.01 as assessed by
two-tailed Student’s t-test.
doi:10.1371/journal.pone.0014671.g006
Figure 7. Indomethacin inhibits kisspeptin-induced vasocon-
striction. Female CD1 mice were anaesthetised, injected intradermally
via the dorsal skin with 5% NaHCO3/saline (Veh), 10nmol KP-10 (KP) or
30pmol Endothelin-1 (ET-1) in the presence or absence of 3nmol
indomethacin (INDO), each containing an equal amount of
99mTc.
Clearance after ten minutes was assessed and compared to total
radioactivity in an uninjected sample. Saline vehicle was adjusted to
100% and results displayed as a % change to controls. Results are
shown as mean 6 SEM, N=6. *=p#0.05 as assessed by one way
ANOVA followed by a Bonferroni’s post test.
doi:10.1371/journal.pone.0014671.g007
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[14,15], is a major condition which threatens the health of both
mother and child during pregnancy. Expression of Kp-10 protein
in syncytiotrophoblasts [4], found at the exchange site of maternal
and foetal blood supplies, could influence maternal vascular tone
as observed in this study. Additionally, this present data provides
evidence for Kp-10 mediated stimulation of mast cell degranula-
tion. Mast cell degranulation has been shown to lead to potent
vasoconstriction in isolated placental vascular beds [40]. Further-
more, decreases in placental blood flow has been associated with
increases in pre-eclampsia, decreased foetal development and
other disorders. Whilst mast cell sub-types are likely to differ
between skin and placenta, both are known to be equally
stimulated by substance P [41]. Therefore, it is possible that
kisspeptins may also be able to activate these mast cells if present in
sufficient amounts locally in the placenta. Alternatively, increases
in local perivascular production of kisspeptins could contribute to
hypertension and plasma extravasation during pregnancy, but also
other disorders in which expression of kisspeptins and Kiss1R
increase. It is difficult to compare the doses used here with the
plasma concentrations observed during pregnancy, but it is
possible that the chronic exposure of mothers and foetus to Kp-
10 during pregnancy as opposed to the acute, local treatment
performed here may elicit the same vascular effects demonstrated.
In conclusion, this is the first study to describe the peripheral
microvascular vasoactive properties of kisspeptins. The doses
required indicate that these effects may not be of physiological
relevance. On the other hand, these effects may become important
in conditions where local tissue levels are high, such as in the
placenta under certain conditions. Furthermore, knowledge of
cardiovascular ‘‘off-target’’ effects could inform the design and
application of kisspeptin-based therapeutics, including both
antagonists and analogs with improved potency [42].
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